Trials / Withdrawn
WithdrawnNCT01557660
Inhaled Treprostinil for PAH: Open-label Extension
Inhaled Treprostinil in Subjects With Pulmonary Arterial Hypertension: An Open-Label, Phase III, International, Multi-Center Study
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- United Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Open-label extension of RIN-PH-302.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | inhaled treprostinil | 0.6mg/mL inhalation solution, up to 12 breaths four times a day |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2018-12-01
- Completion
- 2018-12-01
- First posted
- 2012-03-19
- Last updated
- 2012-03-26
Source: ClinicalTrials.gov record NCT01557660. Inclusion in this directory is not an endorsement.